- Home
- LYEL vs TGTX Comparison
LYEL vs TGTX Comparison
Compare LYEL & TGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LYEL | TGTX |
|---|---|---|
| Founded | 2018 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 681.3M | 5.5B |
| IPO Year | 2021 | 1995 |
Fundamental Metrics
Financial Performance| Metric | LYEL | TGTX |
|---|---|---|
| Price | $33.51 | $30.95 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | $25.00 | ★ $54.75 |
| AVG Volume (30 Days) | 64.7K | ★ 1.6M |
| Earning Date | 11-12-2025 | 11-03-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 2.78 |
| Revenue | $41,000.00 | ★ $531,898,000.00 |
| Revenue This Year | N/A | $87.88 |
| Revenue Next Year | N/A | $48.75 |
| P/E Ratio | ★ N/A | $10.78 |
| Revenue Growth | N/A | ★ 100.88 |
| 52 Week Low | $7.65 | $25.28 |
| 52 Week High | $35.16 | $46.48 |
Technical Indicators
Market Signals| Indicator | LYEL | TGTX |
|---|---|---|
| Relative Strength Index (RSI) | 73.81 | 46.68 |
| Support Level | $32.00 | $30.40 |
| Resistance Level | $34.78 | $32.30 |
| Average True Range (ATR) | 2.50 | 1.13 |
| MACD | 0.36 | -0.00 |
| Stochastic Oscillator | 88.67 | 51.75 |
Price Performance
Historical ComparisonAbout LYEL Lyell Immunopharma Inc.
Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.
About TGTX TG Therapeutics Inc.
TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T), and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries.